Mr. Dane Stevens reports

OPTIMI HEALTH COMPLETES MDMA EXPORT FOR PTSD TREATMENT UNDER AUSTRALIA'S AUTHORISED PRESCRIBER SCHEME

Optimi Health Corp. has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme.

The export included 1,000 of Optimi's MDMA capsules in a standardized 60-milligram dosage form, supplied for use in authorized clinical programs for the treatment of posttraumatic stress disorder (PTSD). The export followed completion of Optimi's first 2026 production cycle, and receipt of the required Australian import permits and Health Canada export permits authorizing international shipment.

Based on standard clinical protocols, this quantity of MDMA represents sufficient supply to support over 300 authorized PTSD treatment sessions under MDMA-assisted therapy programs.

Patient-reported outcomes (PROs) are being collected by the Australian National University (ANU), which is developing one of the most comprehensive real-world evidence (RWE) data sets to date on MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD).

Under the current framework, the Australian Department of Veterans' Affairs (DVA) offers reimbursement for eligible veterans receiving psychedelic-assisted therapy when delivered in accordance with program requirements.

According to the Australian Bureau of Statistics, approximately 5 to 6 per cent of Australians experience PTSD in a given year, representing roughly 1.3 million to 1.5 million people, with higher prevalence among veterans and first responders.

Optimi holds a drug establishment licence issued by Health Canada that authorizes the manufacture of the MDMA capsules for regulated therapeutic use, including the treatment of posttraumatic stress disorder (PTSD), where permitted by local authorities.

The company's licensed Australian pharmacy partner acts as importer of record and national distributor, supplying authorized clinics across Australia in accordance with local regulatory requirements. This delivery enables participating clinics to proceed with MDMA-assisted therapy for eligible patients.

About Optimi Health Corp.

Optimi Health is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, good-manufacturing-practice-compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

We seek Safe Harbor.